bangladesh pharma market dynamics 2 q 2012
DESCRIPTION
TRANSCRIPT
![Page 1: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/1.jpg)
Pharma Market Dynamics
2Q 2012
![Page 2: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/2.jpg)
• Confidentiality Statement
This presentation is solely for the use of IMS clients. No part of it may be circulated, quoted or reproduced for distribution outside of the client organization without prior written approval of IMS Health
![Page 3: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/3.jpg)
•Bangladesh Pharma Market
![Page 4: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/4.jpg)
Bangladesh pharma market: Eskayef is the number 6 company with 4.74% market share
4
18.42
9.52 8.88
5.33 4.93 4.74 4.31 4.12 4.03 3.73
SQUARE INCEPTA BEXIMCO OPSONIN RENATA ESKAYEF A.C.I. ACME ARISTO DRUGINTL
Share %
![Page 5: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/5.jpg)
Evolution of market share: Top 10 Companies Recent data indicates good performance of Incepta, Opsonin, Renata & DI
5
MAT ~ 06/2012 YTD ~ 06/2012 QTR ~ 06/2012
SQUARE 18.42 18.17 17.13
INCEPTA 9.52 9.70 9.78
BEXIMCO 8.88 8.75 8.49
OPSONIN 5.33 5.44 5.47
RENATA 4.93 5.02 5.14
ESKAYEF 4.74 4.74 4.71
A.C.I. 4.31 4.16 4.22
ACME 4.12 4.20 4.07
ARISTO 4.03 4.08 4.07
DRUG INTL 3.73 3.83 3.97
![Page 6: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/6.jpg)
• The Antibiotics Molecules
![Page 7: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/7.jpg)
Antibiotic Market: Top 12 Molecules represents 90% of the 1700 Crore Taka Market
7
17.63
15.79
11.85 10.96
7.68 6.59 6.55
5.47
2.68 1.98 1.81 1.32
Share %
![Page 8: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/8.jpg)
Clindamycin (39% gr) is the highest growing molecule, followed by Cefuroxime (19% gr)
8
38.80
19.39 18.12 17.76 15.73
6.65
0.65 0.33
-4.11 -4.32 -5.57
-10.29
Growth %
![Page 9: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/9.jpg)
Top Companies in Antibiotic Market: ESK number 8 Renta 3, ACI 5, Sanofi 9
9
22.29
7.47 6.77 6.43 6.16
5.20 5.11 5.09 4.75 3.47
SQUARE INCEPTA RENATA BEXIMCO A.C.I. ACME OPSONIN ESKAYEF SANOFIAVN
ARISTO
Share %
![Page 10: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/10.jpg)
Antibiotic Market: Incepta & Opsonin have high growth
10
22.29
7.47 6.77 6.43 6.16
5.20 5.11 5.09 4.75 3.47
6.99
23.97
12.99
8.85
12.67
1.27
17.67
9.73
6.19
4.45
SQUARE INCEPTA RENATA BEXIMCO A.C.I. ACME OPSONIN ESKAYEF SANOFIAVN
ARISTO
Share % Growth %
![Page 11: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/11.jpg)
Antibiotic Market: 4 companies in top 10 are loosing share
11
22.29
7.47 6.77 6.43 6.16 5.20 5.11 5.09 4.75
3.47
-1.11
14.57
4.48
0.63
4.05
-6.47
8.72
1.39
-2.06
-3.34 SQUARE INCEPTA RENATA BEXIMCO A.C.I. ACME OPSONIN ESKAYEF SANOFI
AVN ARISTO
Share % Share Growth %
![Page 12: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/12.jpg)
• Cefuroxime Axetil Market
![Page 13: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/13.jpg)
13
Cefuroxime Market: 78% mkt in 3 divisions: 90% in 4 divisions
Dhaka 37%
Chittagong 21%
Rajshahi 20%
Khulna 12%
Barisal 6%
Sylhet 4%
Share %
![Page 14: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/14.jpg)
14
Cefuroxime: market growth is driven by North Bengal Growth in DHK & CHT is lower than national growth (19%)
37.40
20.77 19.73
12.13
6.04 3.93
16.71 14.20
27.90
19.14
29.97
20.02
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
Share % Growth %
![Page 15: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/15.jpg)
15
Kilmax: DHK division doing wonderful! Under-performing in North Bengal & Barisal
5.13
4.36 4.07
4.51
3.56
4.79
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
MS %
![Page 16: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/16.jpg)
16
Kilmax: DHK having high MS, still growing Growth improvement opportunity in CHT
5.13 4.36 4.07 4.51 3.56 4.79
37.67
-0.20
47.65
13.52
49.84
9.43
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
MS % Gr %
![Page 17: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/17.jpg)
17
Furosef VS. Kilmax: High market share gap (13%) in CHT, low gap in RAJ (7%)
17.19 17.81
11.66
15.53 15.49
17.55
5.13 4.36 4.07 4.51
3.56 4.79
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
MS %
FUROCEF-RTA KILMAX-ESF
![Page 18: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/18.jpg)
18
Kilbac Vs. Kilmax: High market share gap in CHT
13.05 14.60
10.86 11.20 11.56 10.87
5.13 4.36 4.07 4.51
3.56 4.79
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
MS %
KILBAC-IAP KILMAX-ESF
![Page 19: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/19.jpg)
19
Kilbac Vs. Kilmax: GAP Analysis
7.92
10.24
6.79 6.69
8.00
6.08
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
KIlbac VS. Kilmax
GAP
![Page 20: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/20.jpg)
20
Top 5 District: Kilmax MS% high in Mymensingh Low in Comilla
4.08
4.82
5.50
3.46
4.21
Dhaka Chittagong Mynensingh Comilla Khulna
Kilmax
Share %
![Page 21: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/21.jpg)
21
Top 5 District: Kilmax growth % high in Mymensingh Negative in Chittagong
9.96 17.12
29.06 20.87 18.91
28.29
-5.29
90.00
39.85 36.93
Dhaka Chittagong Mynensingh Comilla Khulna
Market Growth
Market Kilmax
![Page 22: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/22.jpg)
• Clindamycin Market
![Page 23: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/23.jpg)
23
Clindamycin Market: Dhaka and Rajshahi division dominates the market
Dhaka 39%
Rajshahi 25%
Khulna 14%
Chittagong 14%
Barisal 5%
Sylhet 3%
Share %
![Page 24: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/24.jpg)
24
39.39
24.75
14.36 13.85
4.40 3.25
45.87
53.83
29.83
11.19
41.71
23.91
Dhaka Rajshahi Khulna Chittagong Barisal Sylhet
Share % Growth %
Clindamycin Market: Very high growth for Dhaka, Rajshahi & Barisal division
![Page 25: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/25.jpg)
25
Incepta VS. Opsonin: Market share GAP is low (7% GAP) in DHK; High in KHL (18%)
31.34 34.51
39.60 36.96
31.67 30.34
23.96 23.62 21.35
23.80
28.02 25.74
Dhaka Rajshahi Khulna Chittagong Barisal Sylhet
CLINDACIN-IAP CLINDAX-OPI
![Page 26: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/26.jpg)
26
Incepta VS. Opsonin: Clindax growth is better than Clindacin in all divisions Major growth difference in Dhaka & Barisal division
11.66
25.44
6.68
-8.12
8.52
-4.89
60.12
37.57
10.61 3.00
40.43
23.78
Dhaka Rajshahi Khulna Chittagong Barisal Sylhet
CLINDACIN-IAP CLINDAX-OPI
![Page 27: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/27.jpg)
• The Anti-ulcer Market
![Page 28: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/28.jpg)
Anti-ulcer Market: 3 ESF brands in top 50 ; QTR figure is encouraging
28
RK~MAT 06/2012
RK~YTD 06/2012
RK~QTR 06/2012
LOSECTIL 2 2 1
PEPTIL-H 21 28 26
ESORAL 29 21 17
![Page 29: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/29.jpg)
• Omeprazole Market
![Page 30: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/30.jpg)
30
Omeprazole Market: 60% mkt in 2 divisions: 90% in 4 divisions
Dhaka 34%
Chittagong 24%
Rajshahi 19%
Khulna 12%
Barisal 7%
Sylhet 4%
Share %
![Page 31: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/31.jpg)
31
Losectil in Omeprazole Market: High MS in KHL Whatever happened in BSL?
19.36 19.21 18.96
22.31
13.94
21.82
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
Losectil
Share %
![Page 32: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/32.jpg)
32
Losectil in Omeprazole Market: High Growth in KHL Lower growth in DHK
19.36 19.21 18.96 22.31 13.94
21.82 22.09
37.14 28.15
100.21
40.31 49.52
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
Losectil
Share % Growth %
![Page 33: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/33.jpg)
33
Seclo Vs. Losectil: market share equally low in all divisions Still losing ground in DHK, RAJ, KHL, SYL
19.36 19.21 18.96
22.31
13.94
21.82
28.20 27.06 26.19 26.74
28.10
19.15
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
MS %
Losectil Seclo
![Page 34: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/34.jpg)
34
Seclo Vs. Losectil: Low gap in KHL Losectil beats Seclo in SYL!
8.84 7.85 7.23
4.43
14.16
-2.67 Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
Losectil Vs. Seclo
GAP
![Page 35: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/35.jpg)
35
Losectil Share % in 5 Major District: High in CHT Low in COM, MYM
20.74
23.48
13.92
17.28
19.67
Dhaka Chittagong Comilla Mynensingh Khulna
MS %
LOSECTIL
![Page 36: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/36.jpg)
36
Seclo Vs. Losectil: 5 Major District
20.74 23.48
13.92
17.28 19.67
27.87 27.34 26.83
36.12
24.00
Dhaka Chittagong Comilla Mynensingh Khulna
MS %
LOSECTIL SECLO
![Page 37: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/37.jpg)
37
GAP Analysis in District Level: High gap in MYM & COM
7.13
3.86
12.91
18.84
4.33
Dhaka Chittagong Comilla Mynensingh Khulna
GAP
20.74 23.48
13.92 17.28
19.67
27.87 27.34 26.83
36.12
24.00
Dhaka Chittagong Comilla Mynensingh Khulna
MS %
LOSECTIL SECLO
![Page 38: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/38.jpg)
• Esomeprazole Market
![Page 39: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/39.jpg)
39
Esomeprazole: Share is good in DHK & BSL Lot of works to be done in North Bengal
3.90 3.38
2.94
3.79 3.91 3.41
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
Esoral
Share %
![Page 40: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/40.jpg)
40
Esomeprazole Market Vs. Esoral Growth
51.67 38.72
79.46 61.60
73.74 55.42
199.39
154.03
218.22 208.34 206.15
161.73
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
Growth %
Esomeprazole Esoral
![Page 41: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/41.jpg)
41
Maxpro Vs. Esoral: Where is the biggest gap?
24.36 24.81
19.57 21.64
25.43
19.44
3.90 3.38 2.94 3.79 3.91 3.41
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
MS %
Maxpro Esoral
![Page 42: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/42.jpg)
42
Maxpro Vs. Esoral: High GAP in CHT & BSL
20.46 21.43
16.63 17.85
21.52
16.03
Dhaka Chittagong Rajshahi Khulna Barisal Sylhet
Maxpro Vs. Esoral
GAP
![Page 43: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/43.jpg)
43
Esoral in Top 5 District
Dhaka Chittagong Comilla Khulna Mynensingh
1 MAXPRO RTA
MAXPRO
RTA
MAXPRO
RTA MAXPRO RTA
MAXPRO
RTA
2 SERGEL HT3 SERGEL HT3
SERGEL
HT3 SERGEL HT3
NEXUM
SQA
3 NEXUM SQA
SOMPRAZ
SPI
NEXUM
SQA ESONIX IAP
SERGEL
HT3
4 ESONIX IAP ESONIX IAP
EXIUM
RD7 MAXIMA ACM
EXIUM
RD7
5 EXIUM RD7 NEXUM SQA ESONIX IAP NEXUM SQA ESONIX IAP
6 ESOTID OPI EXIUM RD7
SOMPRAZ
SPI EXIUM RD7
ESORAL
ESF
7 ESORAL ESF ESORAL ESF
ESOTID
OPI PROGESIC IAP
ESOTID
OPI
8 PROGESIC IAP ESOTID OPI NESO ATP SOMPRAZ SPI
PROGUT
PPH
9 NEPTOR SDZ ESOLOK IBN
ESORAL
ESF ESOTID OPI
SOMPRAZ
SPI
10 NESO ATP
PROGUT
PPH
MAXIMA
ACM NESO ATP
OPTON
BXM ?
![Page 44: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/44.jpg)
• The Anti-ulcer Market:
• Promotional Preference
![Page 45: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/45.jpg)
45
CHT: Important for Ranitidine market
24.26 23.71 23.11 22.72
27.96
Omeprazole Pantoprazole Esomeprazole Rabeprazole Ranitidine
Chittagong
![Page 46: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/46.jpg)
46
RAJ: Important for Pantoprazole
18.55 19.88
18.67 17.04
15.76
Omeprazole Pantoprazole Esomeprazole Rabeprazole Ranitidine
Rajshahi
![Page 47: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/47.jpg)
47
DHK: Important for Rabeprazole & Ranitidine
34.18
34.77 34.97
36.47
36.11
Omeprazole Pantoprazole Esomeprazole Rabeprazole Ranitidine
Dhaka
![Page 48: Bangladesh pharma market dynamics 2 q 2012](https://reader033.vdocuments.net/reader033/viewer/2022061201/547a8492b4af9fda158b4b4c/html5/thumbnails/48.jpg)